

*Program za napredovalo srčno popuščanje  
in transplantacije srca  
KO za kardiologijo  
UKC Ljubljana*



---

## Transtiretinska amiloidoza srca ATTR-CM

---

doc. dr. Gregor Zemljič, dr.med.


junij 2024

# HFpEF




bazen bolnikov s **starostno (wt)ATTR-CM**

**30 – 50 %**




Homogeneous response to treatment  
Several pharmacological and non-pharmacological interventions with established benefit on CV mortality and HF hospitalizations  
*«One size fits all approach»*



Heterogeneous population  
No effective treatments on CV mortality  
Benefit of decongestion and MRA (trend with Candesartan and ARNI) on HF hospitalizations  
Benefit of lifestyle interventions on symptoms and QoL  
*«Phenotype-specific treatment»*

**wtATTR**



[1-s2.0-S0033062020300839-gr3\\_lrg.jpg \(3160x1953\) \(els-cdn.com\)](#)

[1-s2.0-S0167527315008335-gr2\\_lrg.jpg \(2318x1519\) \(els-cdn.com\)](#)




Study	Year	Sample size	Design	Age mean or median (males' percentage %)	Hypertension %	DM%	CAD	Diagnosis of amyloidosis	Prevalence of ATTR
Esther Gonzalez-Lopez/Spain	2015	120	Prospective analysis	82 (males 41%)	84%	37%	9%	99m Tc-DPD scan. Followed by TTR gene test if scan is positive	16 patients (13.3%)
Omar F. AbouEzzeddine/USA	2021	286	Prospective analysis	78 (males 52%)	96%	50%	65%	99m Tc-pyrophosphate scintigraphy	8 patients (6%)
Ana Devesa/Spain	2021	58	Prospective analysis	79 (males 54%)	83%	36%	14%	99m Tc-DPD scan then TTR gene testing if scan is positive	3 patients (5%)
Saberio Lo Presti/USA	2019	100	Retrospective analysis	76 (males 64%)	85%	32%	34%	99mTc-PYP	19 patients (19%)
Selma F. Mohammed/USA	2013	106	Retrospective analysis	74 (males 43%)	78%	42%	62%	Autopsy and histological analysis	18 patients (17%)

**5 – 19 %**



# Preživetje: HFpEF vs. amyloidna CM vs. starostna ATTR-CM


Pomembne razlike v prognozi!





# Starostna ATTR (wild-type) vs. dedna ATTR (mutation)




## Pathophysiology of transthyretin amyloidosis



Wild-type (wtATTR)

Hereditary (hATTR)

## Age of onset of different phenotypes




# Starostna (wt)ATTR-CM


## Mehanizmi srčne okvare in opozorilni znaki






Medcelično kopičenje




Kopičenje v žilni steni




Lokalno kopičenje



# Preživetje: Amyloidoza luhkih verig (AL) vs. starostna ATTR-CM



## Pomembna razlika v prognozi!






# Starostna (wt)ATTR-CM: kako postaviti diagnozo?

## Simptomi in znaki srčnega popuščanja



## Scintigrafija skeleta




## UZ srca




## Anamneza sindroma karpalnega kanala



## MR srca



## Biomarkerji






# wtATTR-CM: UZ najdbe




- ─ Koncentrična zadebelitev sten
- ─ Diastolična disfunkcija levega prekata
- ─ Perikardialni izliv
- ─ Povečana preddvora
- ─ Zadebeljen interatrijski septum

- ─ Znižane hitrosti tkivnega doplerja ( $S'$ ,  $E'$ ,  $A'$ )
- ─ **UZ točkovno sledenje:** „apical sparing“ - ohranjena vzdolžna deformacija apikalnih segmentov





# wtATTR-CM: Scintigrafija skeleta - SPECT/CT






Courtesy of Dr. Štalc:

# Postavitev diagnoze wtATTR-CM

## Algoritem



V več kot >70% diagnoza postavljena brez potrebe po biopsiji




# Od prvega opisa amiloidoze do ...



Amiloid = starch

latin - *amylum*,  
greek - ἄμυλον *amylon*



[Amyloidfibrils.png \(374x230\) \(kenyon.edu\)](#)




Rudolf Virchow

[Rudolf Virchow NLM3 - Rudolf Virchow - Wikipedia](#)




# ...zdravljenja ATTR-CM s tafamidisom



## Vpliv na preživetje



## Vpliv na kvaliteto življenja



# 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

With the special contribution of the Heart Failure Association (HFA) of the ESC

## Recommendations for treatment of patients with HF and amyloidosis

Tafamidis is recommended in patients with genetic testing proven hereditary hTTR-CMP and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.

I	B
I	B

Tafamidis is recommended in patients with wtTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality.

# Ambulanta za infiltrativne bolezni in amiloidozo srca

## Značilnosti bolnikov



	wtATTR-CM	vATTR-PN/CM	AL-CM
All patients (n)	148	5	42
Deceased (n, %)	22 (15%)	1 (20%)	12 (28%)
Heart Tx (n, %)	0 (0%)	1 (20%)	3 (7%)
In diagnostic process (n)	4	1	3
Male (n, %)	115 (78%)	2 (40%)	27 (65%)
Age (years)	79±6	46±11	68±10
Carpal tunnel syndrome (n, %)	93 (63%)	1 (20%)	4 (9%)
Latency between CTS and ATTR-CM (years)	9.3±3.6	NA	NA

# Ambulanta za infiltrativne bolezni in amiloidozo srca

## Bolniki na tafamidis



	wtATTR-CM	mATTR-CM
Patients currently monitored (n)	126	3
NYHA I (n, %)	8 (6%)	3 (100%)
NYHA II (n, %)	79 (63%)	0 (0%)
NYHA III (n, %)	25 (20%)	0 (0%)
NYHA IV (n, %)	14 (11%)	0 (0%)
On Tafamidis (n, %)	84 (67%)	3 (100%)
Awaiting Tafamidis initiation (n, %)	3 (2%)	0

# „Standardna“ terapija srčnega popuščanja pri bolnikih s **starostno ATTR-CM**



	<i>Yes</i>	<i>Sometimes</i>	<i>No</i>
Diuretics ± aldosterone antagonists	<input checked="" type="checkbox"/>		
Renin-angiotensin system inhibitors		<input type="checkbox"/>	
Beta-adrenoreceptor blockers		<input type="checkbox"/>	
Alpha-1-adrenoreceptor agonists		<input type="checkbox"/>	
Calcium channel blockers			<input checked="" type="checkbox"/>
Digoxin *			<input checked="" type="checkbox"/>

- HFpEF - **SGLT2 inhibitorji**



# Starostna (wt)ATTR-CM: kdaj torej pomisliti?

Screen for ATTR!

**ESC**  
European Society  
of Cardiology

European Heart Journal (2021) 42, 1554–1568  
doi:10.1093/euroheartj/ehab072

**SPECIAL ARTICLE**  
Heart failure and cardiomyopathies

## Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo Garcia-Pavia <sup>1,2,3,\*</sup>, Claudio Rapezzi<sup>4,5</sup>, Yehuda Adler<sup>6</sup>, Michael Arad<sup>7</sup>,



Increased LV wall thickness  
without dilated LV  
on echocardiogram

+ ≥1 of the following Red-flags

Category	Red-flags
Demographic	Elderly men over the age of 60 years
Family history	Progressive neuropathy HF at early age
Clinical history	HFpEF in the absence of hypertension Bilateral carpal tunnel syndrome Lumbar spinal stenosis Newly diagnosed hypertrophic cardiomyopathy over the age of 60 years Low flow aortic valve stenosis Angina despite normal coronary angiogram Repeated episodes of embolic stroke Pacemaker implantation for an advanced atrioventricular block or symptomatic bradycardia
Clinical examination	Signs of right-sided HF Intractable pleural effusions Signs of peripheral neuropathy Orthostatic hypotension
Imaging	Low QRS voltage or pseudo-infarction pattern on ECG Any heart block on ECG Atrial fibrillation on ECG Right ventricular hypertrophy on Echo Biventricular enlargement with normal ventricular chamber size on Echo Atrial septal or cardiac valve thickening on Echo Pericardial effusion on Echo Restrictive filling pattern on Echo Apical sparing pattern on Echo CMR with LGE
Alert signs	Intolerance to standard HF medications: ACE-I, ARB, beta-blockade, CCB, digitalis Symptomatic hypotension or resolution of hypertension in previously hypertensive patients

- HFpEF
- Zadebeljene stene LP( $\geq 1,2$  cm)
- 1 „red –flag“ sign: cardiac or extracardiac



## ...in kam poslati?

---

- **Ambulanta za infiltrativne bolezni in amiloidozo srca**
  - del Programa za napredovalo srčno popuščanje in transplantacije srca,  
KO za kardiologijo, UKC Ljubljana
  - [amiloidoza.srca@kclj.si](mailto:amiloidoza.srca@kclj.si)
  - doc. dr. Gregor Zemljič, dr.med., 01 522 8545
  - dr. Sabina Frljak, dr.med., 01 522 8537
  - izr. prof. dr. Gregor Poglajen, dr.med. (sarkoidoza srca)



# Hvala za pozornost!



## Advanced Heart Failure and Transplantation Centre

Bojan Vrtovec, MD, PhD

Gregor Poglajen, MD, PhD

Sabina Frljak, MD, PhD

Gregor Zemljič, MD, PhD

Andraž Cerar, MD, PhD

Renata Okrajšek, MD, PhD

Miran Šebeštjen, MD, PhD

Neža Žorž, MD

Simon Koletnik, RN

Vesna Vovk, RN

